Caprock Group LLC Invests $538,000 in argenex SE $ARGX

Caprock Group LLC purchased a new stake in argenex SE (NASDAQ:ARGX) in the third quarter, HoldingsChannel reports. The firm purchased 755 shares of the company’s stock, valued at approximately $538,000.

Several other large investors have also recently bought and sold shares of ARGX. Mirae Asset Global Investments Co. Ltd. raised its position in shares of argenex by 91.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock worth $6,511,000 after acquiring an additional 4,217 shares during the last quarter. Allianz Asset Management GmbH raised its holdings in argenex by 21.3% during the 3rd quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock worth $2,708,000 after purchasing an additional 645 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in argenex by 14.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 211,330 shares of the company’s stock worth $162,160,000 after purchasing an additional 26,343 shares during the last quarter. Alta Wealth Advisors LLC acquired a new position in argenex during the 3rd quarter valued at about $623,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of argenex by 27.1% in the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,934 shares of the company’s stock valued at $1,066,000 after purchasing an additional 412 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Up 2.6%

Shares of ARGX stock opened at $843.55 on Wednesday. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62. The firm has a fifty day moving average of $833.64 and a 200-day moving average of $804.22. The company has a market capitalization of $52.20 billion, a price-to-earnings ratio of 36.22, a P/E/G ratio of 0.71 and a beta of 0.37.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Morgan Stanley increased their price objective on shares of argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a report on Thursday, December 4th. Wedbush reissued an “outperform” rating and issued a $1,000.00 price target on shares of argenex in a research note on Wednesday, January 14th. Wells Fargo & Company lifted their price objective on argenex from $1,264.00 to $1,317.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Robert W. Baird lowered argenex from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 18th. Finally, Truist Financial raised their target price on argenex from $950.00 to $1,030.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $986.78.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.